Circassia, a biotech spin-out of Imperial College London developing cat and other allergy treatments, announces plans for $285m initial public offering.
Circassia, a biotechnology developing treatments for cat, grass, and other allergies, has revealed aims of raising a £175m ($285m) initial public offering (IPO), making it one of the largest UK floats in recent years. The immunotherapy developer’s IPO could mark a bumper pay day for Imperial College London’s (ICL) tech transfer unit Imperial Innovations. The…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
